Cargando…
Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
BACKGROUND: Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal no...
Autores principales: | Bakır, Mustafa, Türel, Özden, Topachevskyi, Oleksandr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529115/ https://www.ncbi.nlm.nih.gov/pubmed/23137037 http://dx.doi.org/10.1186/1472-6963-12-386 |
Ejemplares similares
-
Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru
por: Gomez, Jorge Alberto, et al.
Publicado: (2013) -
Pneumococcal Nasopharyngeal Carriage in Young Healthy Children After Pneumococcal Conjugate Vaccine in Turkey
por: Arvas, Ahmet, et al.
Publicado: (2017) -
Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
por: Sevilla, J. P., et al.
Publicado: (2020) -
Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools
por: Chaiyakunapruk, Nathorn, et al.
Publicado: (2011) -
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)